Moving towards treatments for spinal muscular atrophy: hopes and limits

Spinal muscular atrophy (SMA), one of the most frequent and devastating genetic disorders causing neuromuscular degeneration, has reached the forefront of clinical translation. The quite unique genetic situation of SMA patients, who lack functional SMN1 but carry the misspliced SMN2 copy gene, creates the possibility of correcting SMN2 splicing by antisense oligonucleotides or drugs. Both strategies showed impressive results in pre-clinical trials and are now in Phase II-III clinical trials. SMN gene therapy approaches using AAV9-SMN vectors are also highly promising and have entered a Phase I clinical trial. However, careful analysis of SMA animal models and patients has revealed some limitations that need to be taken very seriously, including: i) a limited time-window for successful therapy delivery, making neonatal screening of SMA mandatory; ii) multi-organ impairment, requiring systemic delivery of therapies; and iii) a potential need for combined therapies that both increase SMN levels and target pathways that preserve/rescue motor neuron function over the lifespan. Meeting these challenges will likely be crucial to cure SMA, instead of only ameliorating symptoms, particularly in its most severe form. This review discusses therapies currently in clinical trials, the hopes for SMA therapy, and the potential limitations of these new approaches.

[1]  Y. Hua,et al.  Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic mouse models , 2015, Genes & development.

[2]  B. Wirth,et al.  SMN regulates axonal local translation via miR-183/mTOR pathway. , 2014, Human molecular genetics.

[3]  R. Finkel,et al.  G.O.17 Results of a phase 2 open-label study of ISIS-SMNRx in patients with infantile (Type 1) spinal muscular atrophy , 2014, Neuromuscular Disorders.

[4]  E. Mercuri,et al.  G.O.19 Results of a phase II study to assess safety and efficacy of olesoxime (TRO19622) in 3–25 years old spinal muscular atrophy patients , 2014, Neuromuscular Disorders.

[5]  E. Bertini,et al.  Results of a Phase II Study to Assess Safety and Efficacy of Olesoxime (TRO19622) in 3- to 25-Year-Old Spinal Muscular Atrophy Patients , 2014 .

[6]  Anirvan Ghosh,et al.  SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy , 2014, Science.

[7]  T. Akay,et al.  Requirement of enhanced Survival Motoneuron protein imposed during neuromuscular junction maturation. , 2014, The Journal of clinical investigation.

[8]  B. Wirth,et al.  How genetic modifiers influence the phenotype of spinal muscular atrophy and suggest future therapeutic approaches. , 2013, Current opinion in genetics & development.

[9]  B. Wirth,et al.  Plastin 3 ameliorates spinal muscular atrophy via delayed axon pruning and improves neuromuscular junction functionality. , 2013, Human molecular genetics.

[10]  K. Mamchaoui,et al.  Shift from Extracellular Signal-Regulated Kinase to AKT/cAMP Response Element-Binding Protein Pathway Increases Survival-Motor-Neuron Expression in Spinal-Muscular-Atrophy-Like Mice and Patient Cells , 2013, The Journal of Neuroscience.

[11]  John T. Dimos,et al.  VPA response in SMA is suppressed by the fatty acid translocase CD36. , 2013, Human molecular genetics.

[12]  Adrian R. Krainer,et al.  Peripheral SMN restoration is essential for long-term rescue of a severe SMA mouse model , 2011, Nature.

[13]  N. Chatauret,et al.  Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. , 2011, Human molecular genetics.

[14]  M. Schroth,et al.  SMA CARNI-VAL Trial Part I: Double-Blind, Randomized, Placebo-Controlled Trial of L-Carnitine and Valproic Acid in Spinal Muscular Atrophy , 2010, PloS one.

[15]  A. Higginbottom,et al.  PTEN depletion rescues axonal growth defect and improves survival in SMN-deficient motor neurons. , 2010, Human molecular genetics.

[16]  A. Grierson,et al.  Systemic Delivery of scAAV9 Expressing SMN Prolongs Survival in a Model of Spinal Muscular Atrophy , 2010, Science Translational Medicine.

[17]  M. Bowerman,et al.  Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. , 2010, Human molecular genetics.

[18]  M. Rich,et al.  Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN , 2010, Nature Biotechnology.

[19]  M. Heisenberg,et al.  P90 Ribosomal s6 kinase 2 negatively regulates axon growth in motoneurons , 2009, Molecular and Cellular Neuroscience.

[20]  M. Schroth,et al.  Phase II Open Label Study of Valproic Acid in Spinal Muscular Atrophy , 2009, PloS one.

[21]  Mitchell R Lunn,et al.  Spinal muscular atrophy , 2008, The Lancet.

[22]  B. Wirth,et al.  Plastin 3 Is a Protective Modifier of Autosomal Recessive Spinal Muscular Atrophy , 2008, Science.

[23]  B. Wirth,et al.  In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate , 2006, Annals of neurology.

[24]  B. Wirth,et al.  Explorer Dysregulation of ubiquitin homeostasis and beta-catenin signaling promote spinal muscular atrophy , 2016 .

[25]  G. Hamilton,et al.  Spinal muscular atrophy: going beyond the motor neuron. , 2013, Trends in molecular medicine.